Paulis Gianni, De Giorgio Giovanni, Paulis Andrea
Department of Urology and Andrology, Peyronie's Care Center, Castelfidardo Clinical Analysis Center, Rome.
Department of Urology and Andrology, Section of Ultrasound Diagnostics, Castelfidardo Clinical Analysis Center, Rome.
Arch Ital Urol Androl. 2024 Oct 29;96(4):12956. doi: 10.4081/aiua.2024.12956.
Peyronie's disease (PD) is characterized by fibrosis of the penile tunica albuginea. Conservative treatment options may involve oral and/or injectable medications.
This case series includes four patients with PD in the first phase. The diagnosis of PD included a medical history; penile palpation; a physical examination of the penis, documenting penile deformity (Kelâmi method); penile dynamic Doppler ultrasound (PDDU) + elastography, measuring the plaque and calculating its volume (cm3), and the deformation index (strain ratio); and the completion of the following questionnaires: IIEF to assess erectile function, VAS to assess pain, and Peyronie's Disease Questionnaire (PDQ) symptom bother to evaluate the psychosexual impact of the disease. Diagnostic follow-up evaluations were conducted before and every 6-12 months throughout the conservative treatment. The four patients were treated at our andrology clinic between January 2019 and November 2023. Our treatment included the following: bilberry, propolis, ginkgo biloba, silymarin, L-carnitine, coenzime Q-10, Boswellia, superoxide dismutase, vitamin E, vitamin C, topical diclofenac gel, propolis cream, and perilesional penile injections with pentoxifylline for cases involving penile plaques with volumes of > 0.100 cm3.
Complete resorption of the PD plaque after treatment occurred in all cases. The disappearance of Peyronie's plaque occurred over a period ranging from 18 to 36 months, in relation to the volume of the plaque.
Despite the limited sample size in our study, these patients verifiably achieved the complete resorption of the affected disease area. Our results will provide useful insights for uroandrological clinical practice. Nevertheless, randomized controlled trials with a larger number of PD patients are needed to demonstrate the effectiveness of multimodal antioxidant treatment.
佩罗尼氏病(PD)的特征是阴茎白膜纤维化。保守治疗方案可能包括口服和/或注射药物。
本病例系列包括4例处于第一阶段的佩罗尼氏病患者。佩罗尼氏病的诊断包括病史;阴茎触诊;阴茎体格检查,记录阴茎畸形(凯拉米法);阴茎动态多普勒超声(PDDU)+弹性成像,测量斑块并计算其体积(立方厘米)以及变形指数(应变率);并完成以下问卷:用于评估勃起功能的国际勃起功能指数(IIEF)、用于评估疼痛的视觉模拟量表(VAS)以及用于评估疾病对心理性影响的佩罗尼氏病问卷(PDQ)症状困扰。在保守治疗前及整个治疗过程中每6 - 12个月进行一次诊断性随访评估。这4例患者于2019年1月至2023年11月在我们的男科诊所接受治疗。我们的治疗包括以下内容:越橘、蜂胶、银杏叶、水飞蓟宾、左旋肉碱、辅酶Q - 10、乳香、超氧化物歧化酶、维生素E、维生素C、外用双氯芬酸凝胶、蜂胶乳膏,对于阴茎斑块体积>0.100立方厘米的病例,在病变周围进行阴茎注射己酮可可碱。
所有病例治疗后佩罗尼氏病斑块均完全吸收。佩罗尼氏斑块的消失时间为18至36个月,取决于斑块的体积。
尽管我们研究中的样本量有限,但这些患者确实实现了病变区域的完全吸收。我们的结果将为泌尿男科临床实践提供有用的见解。然而,需要对更多佩罗尼氏病患者进行随机对照试验,以证明多模式抗氧化治疗的有效性。